MiNK Therapeutics, Inc. (INKT)

Market Cap	42.83M +41.1%
Revenue (ttm)	n/a
Net Income	-12.36M
EPS	-3.02
Shares Out	4.69M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	36,670
Open	8.74
Previous Close	8.56
Day's Range	8.58 - 9.19
52-Week Range	6.34 - 76.00
Beta	0.35
Analysts	Buy
Price Target	35.00 (+283.56%)
Earnings Date	May 14, 2026

About INKT

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab plus balstilimab with ramucirumab and paclitaxel for patients wi...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 15, 2021
• Employees: 23
• Stock Exchange: NASDAQ
• Ticker Symbol: INKT
• Website: https://minktherapeutics.com

Analyst Summary

According to 2 analysts, the average rating for INKT stock is "Buy." The 12-month stock price target is $35.0, which is an increase of 283.56% from the latest price.

Price Target

$35.0

(283.56% upside)

Analyst Consensus: Buy